Whitehawk Therapeutics Inc

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

Whitehawk Therapeutics presented two real-world analyses at IGCS 2026 supporting MUC16 as a durable ADC target in ovarian cancer. MUC16 expression remained high and stable after standard-of-care therapies and showed less treatment-associated variation than competing ADC targets FRα, TROP2 and NaPi2b; high MUC16 expression was also prognostic of poor real-world overall survival in HGSOC, the subtype accounting for roughly 70% of ovarian cancer cases. The findings reinforce the scientific rationale for HWK-016, Whitehawk's MUC16-directed ADC in an ongoing Phase 1 trial (NCT07470853), and stem from a previously announced collaboration with Tempus AI.

•1mo ago

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

Whitehawk Therapeutics presented two real-world analyses at the IASLC 2026 World Conference on Lung Cancer supporting PTK7 as a durable, clinically relevant ADC target in pretreated EGFR wild-type non-small cell lung cancer. The analyses found PTK7 expression remained largely stable after standard-of-care chemotherapy, immunotherapy and TKI treatment, with less treatment-associated variation than late-stage ADC targets including MET, PD-L1 and ITGB6. A separate analysis showed PTK7 expression was not associated with real-world overall survival, positioning it as a target-engagement biomarker rather than a prognostic marker. The data reinforce the scientific rationale for HWK-007, Whitehawk's PTK7-directed ADC in an ongoing Phase 1 trial across EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancers, and stem from a collaboration with Tempus AI.

•1mo ago

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics reported a Q2 net loss of $16.6 million, or $0.20 per share, with no revenue for the period. R&D expenses decreased to $12.9 million compared to the prior year's quarter which included a one-time license fee. The company bolstered its balance sheet with $190.0 million in cash and investments following an $87.5 million private placement in May. Management projects this capital will fund operations into the second half of 2028. Operationally, Whitehawk is enrolling patients in Phase 1 trials for HWK-007 and HWK-016 and remains on track to initiate the HWK-206 trial in Q3 2026. Recent strategic moves include option agreements with Hangzhou DAC and a collaboration with Biocytogen to expand its ADC platform.

•2mo ago

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Whitehawk Therapeutics has entered a global collaboration with Biocytogen to develop bispecific antibody-drug conjugates (BsADCs). Biocytogen will provide access to up to five bispecific antibodies from its RenLite platform, which Whitehawk will evaluate using its proprietary ADC linker-payload technologies. Whitehawk retains the option to advance resulting candidates with global rights and full program control, supporting its ambition to deliver new ADC INDs within the next 12-24 months.

•3mo ago

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics presented real-world analysis at ASCO 2026 confirming SEZ6 as a highly expressed target in small cell lung cancer (SCLC) and other neuroendocrine tumors. The data showed SEZ6 expression is at least 3-fold higher than established ADC targets like HER2, B7-H3, and DLL3 in SCLC, and 2- to 6-fold higher in prostate neuroendocrine carcinoma. These findings support the development of HWK-206, a biparatopic SEZ6-directed ADC, with an IND submission expected in mid-2026 and Phase 1 trials planned for Q3 2026.

•5mo ago

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics signed an option agreement with Hangzhou DAC to access the CPT113 linker-payload technology for up to five new internally developed ADC programs. The deal allows Whitehawk to retain global rights and full program control while selecting targets and sourcing antibodies, with IND submissions expected over the next 12-24 months. Phase 1 dose-escalation trials for HWK-007 and HWK-016 are currently enrolling, with HWK-007 data to be presented at ASCO and initial data for both expected in the first half of 2027.

•5mo ago

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics reported a cash balance of $123.0 million as of March 31, 2026, sufficient to fund operations into 2028, while Phase 1 dose-escalation trials for HWK-007 and HWK-016 remain ongoing. Management plans to submit an IND for HWK-206 in mid-2026, with initial data for the ongoing Phase 1 trials anticipated in the first half of 2027. Financially, the company posted a Q1 net loss of $22.2 million, driven by $17.2 million in R&D expenses, compared to a net income of $73.0 million in the prior-year quarter which included an $87.4 million gain on the sale of Aadi Subsidiary.

•5mo ago